The results suggest that linezolid is a safe and effective treatment for Gram-positive bacterial infections.
Illustration of Corynebacterium diphtheria bacteria, rod-shaped Gram-positive bacteria that cause respiratory infections, diphtheria, and skin lesions. Photo: Shutterstock.
According to a study published in the Journal of Intensive Medicine, it was found that approximately 80% of patients in intensive care during one study showed clinical improvement in Gram-positive bacterial infections after treatment with linezolid based on data from more than 300 people. showed improvement.
The researchers stressed that bacterial infections remain a challenge in the management of critically ill patients because many Gram-positive pathogens have become resistant to multiple drug options.
The authors stated that linezolid demonstrated efficacy against L. Staphylococcus infection with methicillin-resistant aureus (MRSA) and skin and soft tissue (SSTI), but its use in critically ill patients in the ICU with Gram-positive infections has not been characterized
Aijia Ma, MD, of Sichuan University West China Hospital, Sichuan, China, and colleagues note that patients were treated with injections of linezolid (200 mg/100 mL) for up to 48 hours after discontinuation of therapy. was treated once daily. of ICU, or death.
“The majority of patients (243) were over the age of 65; 90 were between the ages of 18 and 65 and 30 were under the age of 18. Nearly two-thirds (67%) were male. RESULTS primary clinical efficacy Success was there (fix or improve), he wrote in his post.
The investigation showed that linezolid was used as second-line and first-line treatment in 232 (63.4%) and 134 (36.6%) patients, respectively.
“The most common strain isolated was Staphylococcus aureus (31% MRSA; 12.6% methicillin-sensitive S. aureus) [MSSA]), followed by Enterococci (6.7% vancomycin-resistant; 9.2% vancomycin-susceptible) and Streptococcus pneumoniae (3.4% multidrug-resistant; 1.7% non-multidrug-resistant),” they noted.
Overall, 82.2% of patients met the criteria for clinical success; 34 (9.3%) were cured and 267 (73%) improved. The clinical success rates for first-line and second-line linezolid treatment were 79.9% and 83.6%, respectively. Failure Rate for Linezolid They were higher for second-line treatment than for first-line (9.5% versus 5.2%).
The clinical success rate was highest against MSSA (93.3%), followed by MRSA (83.8%). Average Daily Dose of Linezolid WS, 1109 mg and average healing time It was 5.1 days.
A total of 8 patients (2.2%) reported linezolid-related adverse events and 4 patients discontinued the drug because of them; None reported serious adverse events related to treatment. low incidence of thrombocytopenia The current study (2 patients) may be related to linezolid avoidance for patients at risk compared to earlier studies, as determined by physicians, and the relatively short duration of linezolid use, the researchers write in their discussion. .
The results show that Is linezolid a safe treatment? and effective for Gram-positive bacterial infections, although physicians should pay close attention to potential side effects and assess individual patient conditions before using linezolid in the clinic, they concluded.
